Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Khellin

$52

  • Brand : BIOFRON

  • Catalogue Number : BD-P0619

  • Specification : 95.0%(GC)

  • CAS number : 82-02-0

  • Formula : C14H12O5

  • Molecular Weight : 260.2

  • Volume : 50mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0619

Analysis Method

HPLC,NMR,MS

Specification

95.0%(GC)

Storage

2-8°C

Molecular Weight

260.2

Appearance

Yellow powder

Botanical Source

Structure Type

Chromones/Flavonoids

Category

SMILES

Synonyms

IUPAC Name

Applications

Density

1.3±0.1 g/cm3

Solubility

Flash Point

218.8±28.7 °C

Boiling Point

482.1±0.0 °C at 760 mmHg

Melting Point

150-154ºC

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2932990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:82-02-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

30958028

Abstract

A series of new visnagin and benzofuran scaffold-based molecules was designed and synthesized as anti-inflammatory and analgesic agents. Biological screening of these compounds showed that they exhibit potent anti-inflammatory/analgesic activity with a safer side effect profile in in vivo mouse models. In vitro cyclooxygenase (COX) inhibition assay showed that the compounds elicit their function through selective COX-2 inhibition. Molecular docking study also revealed the ability of the compounds to correctly recognize the active site and achieve noncovalent binding interactions with key residues therein. The best combined profile of anti-inflammatory, analgesic and COX-2 selective inhibition properties in association with low gastrotoxicity was displayed by the analogs 8, 11b and 19d, which can be considered as promising leads for further future optimization.

KEYWORDS

COX-2 selective inhibitors; molecular docking; ulcerogenicity; visnagin; benzofuran.

Title

Visnagin and benzofuran scaffold-based molecules as selective cyclooxygenase-2 inhibitors with anti-inflammatory and analgesic properties: design, synthesis and molecular docking

Author

Hazem Sa Khalil 1, Nada K Sedky 2, Kamelia M Amin 3, Omaima M Abd Elhafez 4, Reem K Arafa 2

Publish date

2019 Apr;

PMID

30798137

Abstract

Acute pancreatitis (AP) is an exocrine dysfunction of the pancreas where oxidative stress and inflammatory cytokines play a key role in induction and progression of the disease. Studies have demonstrated that antioxidant phytochemicals have been effective in improving pancreatitis condition, but there are no clinically approved drugs till date. Our study aims to assess the preventive activity of visnagin, a novel phytochemical isolated from Ammi visnaga against cerulein induced AP. Male Swiss albino mice were divided into six groups (n = 6, each group) comprising of normal control, cerulein control, seven day pre-treatment with visnagin at three dose levels; visnagin low dose (10 mg/kg), visnagin mid dose (30 mg/kg), visnagin high dose (60 mg/kg) and visnagin control (60 mg/kg). AP was induced by six injections of cerulein (50 μg/kg, i.p.) on the 7th day and the animals were sacrificed after 6 h of last cerulein dose. Various markers of pancreatic function, oxidative stress and inflammation were assessed. Visnagin was found to be effective in reducing plasma amylase and lipase levels, reduced cerulein induced oxidative stress. Visnagin dose dependently decreased the expression of IL-1β, IL-6, TNF-α and IL-17. It attenuated the levels of nuclear p65-NFκB. Visnagin improved the antioxidant defence by improving Nrf2 expression and halted pancreatic inflammation by suppressing NFκB and nitrotyrosine expression in the acinar cells. Further, it attenuated the expression of markers of multiple organ dysfunction syndrome and reduced inflammatory cytokines in lungs and intestine. Cumulatively, these findings indicate that visnagin has substantial potential to prevent cerulein induced AP.

KEYWORDS

Acute pancreatitis; Inflammation; NFκB; Nitrotyrosine; Nrf2; Visnagin.

Title

Visnagin attenuates acute pancreatitis via Nrf2/NFκB pathway and abrogates associated multiple organ dysfunction

Author

Lakshmi Priya Pasari 1, Amit Khurana 1, Pratibha Anchi 1, Mohd Aslam Saifi 1, Shivaraju Annaldas 1, Chandraiah Godugu 2

Publish date

2019 Apr;

PMID

30694454

Abstract

Melanoma is a cancer of melanocyte cells and has the highest global incidence. There is a need to develop new drugs for the treatment of this deadly cancer, which is resistant to currently used treatment modalities. We investigated the anticancer activity of visnagin, a natural furanochromone derivative, isolated from Ammi visnaga L., against malignant melanoma (HT 144) cell lines. The singlet oxygen production capacity of visnagin was determined by the RNO bleaching method while cytotoxic activity by the MTT assay. Further, HT 144 cells treated with visnagin were also exposed to visible light (λ ≥ 400 nm) for 25 min to examine the illumination cytotoxic activity. The apoptosis was measured by flow cytometry with annexin V/PI dual staining technique. The effect of TNF-α secretion on apoptosis was also investigated. In standard MTT assay, visnagin (100 µg/mL) exhibited 80.93% inhibitory activity against HT 144 cancer cell lines, while in illuminated MTT assay at same concentration it showed lesser inhibitory activity (63.19%). Visnagin was induced apoptosis due to the intracellular generation of reactive oxygen species (ROS) and showed an apoptotic effect against HT 144 cell lines by 25.88%. However, it has no effect on TNF-α secretion. Our study indicates that visnagin can inhibit the proliferation of malignant melanoma, apparently by inducing the intracellular oxidative stress.

KEYWORDS

Ammi visnaga L.; Apoptosis; Malignant melanoma; Visnagin.

Title

The anticancer activity of visnagin, isolated from Ammi visnaga L., against the human malignant melanoma cell lines, HT 144

Author

Fatma AydogmuS-ozturk 1 2 3, Humera Jahan 3, Neslihan Beyazit 4, Keriman Gunaydın 5, Muhammad Iqbal Choudhary 3 6 7

Publish date

2019 Apr